Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Accounts Payables (2019 - 2025)

Legend Biotech filings provide 7 years of Accounts Payables readings, the most recent being $83.0 million for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 115.03% to $83.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $83.0 million, a 115.03% increase, with the full-year FY2025 number at $83.0 million, up 115.03% from a year prior.
  • Accounts Payables hit $83.0 million in Q4 2025 for Legend Biotech, down from $102.5 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $102.5 million in Q3 2025 to a low of $7.0 million in Q4 2021.
  • Median Accounts Payables over the past 5 years was $32.9 million (2022), compared with a mean of $40.8 million.
  • Biggest five-year swings in Accounts Payables: surged 367.03% in 2022 and later fell 6.8% in 2023.
  • Legend Biotech's Accounts Payables stood at $7.0 million in 2021, then surged by 367.03% to $32.9 million in 2022, then fell by 6.8% to $30.7 million in 2023, then grew by 25.92% to $38.6 million in 2024, then surged by 115.03% to $83.0 million in 2025.
  • The last three reported values for Accounts Payables were $83.0 million (Q4 2025), $102.5 million (Q3 2025), and $75.4 million (Q2 2025) per Business Quant data.